Additional file 4: **Figure S3** Pembrolizumab exposure for patients treated with pembrolizumab in the nonadjuvant setting at doses of 200 mg Q3W (*N* = 913) (a), 2 mg/kg Q3W (*N* = 542) (b), 10 mg/kg Q3W (*N* = 428)(c), 10 mg/kg Q2W (*N* = 117) (d). Figure includes ADA samples with corresponding PK concentrations. Samples taken >2 times the scheduled time were excluded. Individual pembrolizumab concentrations for the patients are represented as dots or crosses and mean value is represented by a black line. For the positive patients (non-TE and TE), all the samples (ADA negative and ADA positive) are “colored.” The confirmed positive ADA samples are indicated by a black circle around the corresponding PK sample. ADA, antidrug antibody; NAb, neutralizing antibody; non-TE, non–treatment-emergent ADA positive; PK, pharmacokinetic; Q2W, every 2 weeks; Q3W, every 3 weeks;

TE, treatment-emergent ADA positive.